Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LiGeR-CRC1
jRCT2051260203Phase 3Recruiting
- Sponsor
- Genmab
- Start
- Oct 2026
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 3, randomised, open-label trial of petosemtamab in colorectal cancer (CRC) (2 arms), sponsored by Genmab. Primary endpoints: Progression-free survival and Objective response rate. Started Oct 2026; status: recruiting.
02
Drugs
petosemtamab
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on jRCT2051260203.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2051260203.